ResMed
RMD
723 hedge funds and large institutions have $24.6B invested in ResMed in 2021 Q4 according to their latest regulatory filings, with 110 funds opening new positions, 238 increasing their positions, 257 reducing their positions, and 62 closing their positions.
77% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 62
5% more funds holding
Funds holding: 686 → 723 (+37)
3% less capital invested
Capital invested by funds: $25.4B → $24.6B (-$783M)
7% less repeat investments, than reductions
Existing positions increased: 238 | Existing positions reduced: 257
1.21% less ownership
Funds ownership: 66.17% → 64.96% (-1.2%)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
35% less call options, than puts
Call options by funds: $41.5M | Put options by funds: $64.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$93.5M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$79M |
| 3 |
AAM
Ardevora Asset Management
London,
United Kingdom
|
+$76.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$66.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$51.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$715M |
| 2 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
-$51.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$48M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$41.2M |
| 5 |
WT
Washington Trust
Westerly,
Rhode Island
|
-$36.3M |
RMD Hedge Fund Activity: Q4 2021 in Review
723 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q4 2021, worth a combined $24.6B — down 3.1% from $25.4B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new RMD positions and 62 closed out — a net gain of 48 holders — while 238 added to existing stakes and 257 trimmed.
The largest buyer was BlackRock, adding an estimated $93.5M. The largest seller was Baillie Gifford & Co, cutting an estimated $715M.
- 723 institutional investors held ResMed (RMD) as of Q4 2021, up from 686 in Q3 2021.
- Funds reported $24.6B of ResMed stock for Q4 2021, down 3.1% quarter-over-quarter.
- 110 funds opened new ResMed positions in Q4 2021 and 62 closed out, a net change of +48 holders.
- The largest ResMed buyer in Q4 2021 was BlackRock, an estimated $93.5M added.
- The largest ResMed seller in Q4 2021 was Baillie Gifford & Co, an estimated $715M sold.
Based on aggregated 13F filings for Q4 2021.